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Summary.-Cell-mediated cytotoxicity (CTX) was studied in meningioma patients
before and within 2 weeks of complete excision of the tumour, using the [3H]-proline
microcytotoxicity test. Three of 7 patients tested before surgery showed specific
CTX, 2 revealed a " non-specific " (tumour-unrelated) response, and 2 were non-
reactive. After surgery, CTX decreased from 84 to 50% in one patient and became
negative in 2 others previously positive. One of 2 patients showing " non-specific"
CTX preoperatively became positive, while the other remained unchanged.
All patients were receiving dexamethasone (DXM) at the time they were tested.
Lymphocyte responses to PHA were not significantly different before or after surgery
(i.e. after prolonged treatment with DXM), from healthy controls.
Blocking activity could be detected in the sera of all 3 patients before surgery.
This activity was not specific for meningiomas. Paradoxically, the same sera did
not inhibit the proliferative response to PHA. Serum from only one patient con-
sistently suppressed the blastogenic response of homologous lymphocytes to PHA.
Inhibitory activity was associated with the IgG fraction of his serum.
MANY reports have been published
estimating immune responses against hu-
man brain tumours in vitro (Brooks et
al., 1972; Levy, Mahaley and Day,
1972; Kumar and Taylor, 1973; Kumar et
at., 1973; Wahlstrom, Saksela and Troupp,
1973; Meyer-Rienecker et al., 1975). Al-
though these reports demonstrate that
the brain can no longer be regarded as
an " immunologically privileged site "
(Medawar, 1948), results are still con-
flicting.
In order to eliminate at least some
of the technical problems, we used a
well-defined [3H]-proline microcytotoxi-
city test (Bean et al., 1973). A benign
tumour (meningioma) was initially select-
ed for study, since such lesions are less
heterogenous and easier to grow in tissue
culture than malignant tumours of the
central nervous system (CNS). Menin-
giomas are common intracranial tumours
and are usually excised completely. Most
of these tumours have a definite chromo-
some loss, both in vivo and in vitro
(Zankl and Zang, 1972).
In a previous study, we demonstrated
the occurrence of a specific cytotoxic
immune response in about 65% of post-
operative meningioma patients tested in
vitro (Pees and Seidel, 1976). The aim
of the present study was to test the
effect of surgery on cellular cytotoxicity
(CTX). Part of the study also assessed
the influence of treatment with dexa-
methasone (DXM), a drug now widely
used in neurosurgery of CNS tumours.
MATERIALS AND METHODS
Target celtt (T).-Biopsy specimens of
CNS tumours were carefully dissected, wash-
ed several times and trypsinized. Primary
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cultures were established either from single-
cell suspensions or small pieces of tumour.
All cultures were maintained in Eagle's
minimal essential medium (MEM) with 1%
non-essential amino acids (NEAA) supple-
mented with 2 mm glutamine, streptomycin
(100 ,tg/ml), penicillin (100 i.u./ml), and 15%
foetal calf serum (FCS). All meningioma
explants grew rapidly, whereas glioblastoma
tissues were much more difficult to establish,
either on account of the proliferation of
contaminating fibroblasts or the paucity of
tumour cells after one or two passages.
One line originating from a glioblastoma
multiforme (I.F.) appeared satisfactory by
morphological criteria and growth charac-
teristics, and was used as a control. Normal
fibroblasts were obtained from explants of
skin biopsy specimens.
All cultures were routinely checked for
fungal and bacterial contamination, and
discarded if infected. The cells were frozen
in liquid N2 as early as possible, and tested
during the first few passages.
Effector cells (E).-For cytotoxicity ex-
periments, lymphoid cells were purified
from venous blood by defibrination, sedi-
mentation with gelatin, and incubation on
a nylon wool column for 30 min at 37°C to
remove adherent cells. After elution from
the column, the cells were treated with
0.84% NH4Cl and washed x3 (O'Toole et
al., 1972a). The final culture medium was
MEM with 10% human AB Rh-+ serum.
Viability was always greater than 95% as
judged by trypan blue exclusion.
For determination of the proliferative
response to phytohaemagglutinin (PHA),
peripheral blood lymphocytes were separated
by defibrination and centrifugation over a
discontinuous Ficoll-Hypaque gradient (Boy-
um, 1968). The cells were washed x 3
and final suspensions prepared in MEM
containing 10% human AB Rh+ serum.
Sera.-Sera were obtained from clotted
aseptically drawn venous blood. Red cells
were removed by centrifugation at 900 g for
10 min. All sera were heat-inactivated at
56°C for 30 min, sterilized by millipore filtra-
tion, and stored in aliquots at -20°C until
use. In some experiments, several normal
sera from AB Rh+ donors were pooled.
Each serum was first tested for its ability
to support growth oftarget cells and mitogen-
stimulated lymphocytes.
Microcytotoxicity test.-Labelling oftarget
cells with [3H]-proline was performed as
described elsewhere (Bean et al., 1973).
Briefly, monolayers were washed in T30
plastic flasks with MEM not containing
NEAA and incubated with 50 ,Ci/ml of
[3H]-proline in proline-deficient MEM for
16-18 h (No. TMM 160, sp. act. 20-30
Ci/mmol, Commissariat 'a l'energie atomique,
France). Thereafter the cells were washed
with excess amounts of NEAA, trypsinized,
and seeded into prefilled (0-1 ml MEM with
10% human AB Rh+ serum) Falcon 3040
microtest plates with a Hamilton syringe
delivering 10 ,ul containing 1000 viable
cells. Target cells were allowed to attach
overnight and effector cells added in 0*1 ml
containing 2 x 105 cells (E: T ratio 200: 1).
The plates were incubated for 50-52 h, and
then inverted, washed x 2 in PBS with
5% FBS, and processed for residual [:H]-
proline as described previously (Pees and
Seidel, 1976). Each assay was performed
in at least 5 replicates.
Reduction (CTX) of target cell 3H
(ct/min) by test lymphocytes was compared
with control lymphocytes giving the highest
ct/min on meningioma tissue according to
the formula:
% CTX = 100x
Highest residual ct/min
with control lymphocytes
Residual ct/min with
test lymphocytes
Highest residual ct/min
with control lymphocytes
To obtain biologically meaningful results,
a minimum of 20% reduction was taken as
a positive cytotoxic reaction. Statistical
analysis was estimated by Wilcoxon's test
with P < 0 05 representing a significant
difference.
Non-specific CTX was defined as a
positive" effect on targets of more than
one histogenic origin. Specific CTX de-
noted a " positive " reaction by an effector
cell preparation limited to meningioma
targets.
Lymphocyte culture.-A volume of 0-1 ml
MEM + 10% human AB Rh+ serum con-
taining 2 x 105 cells was added to a micro-
test plate (Falcon No. 3040). An additional
0-1 ml of medium containing PHA-P (Difco)
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was added to give a final volume of 0-2 ml
and 25 ,tg PHA/ml culture fluid. Cultures
were set up in at least 5 replicates, and
placed in a 37°C incubator with a humidified
atmosphere and 5% CO2 for 66 h. DNA
synthesis was measured by labelling with
1 IuCi of [3H] thymidine (sp. act. 400 mCi/
mmol) 16 h before harvesting. Cultures
were collected by precipitation on to glass-
fibre filters with a multiple automatic
sample harvester. The optimal conditions
for this system using human lymphocytes
have been defined elsewhere (Pees and
Pappas, 1975).
Blocking studies.-Test sera were added
at least 60 min before the addition of effector
cells. In some experiments, target cells
were plated in 10% normal serum and
blocking was determined by adding 10 IlI
of test serum, the control having the same
volume of normal serum. Other experi-
ments were performed, using several plates
with target cells attached in MEM containing
either normal sera or test sera from the
outset. In either event, blocking activity
was calculated from the formula:
%/ Blocking=
% CTX in % CTX in
normal sera autologousserax 100.
% CTX in normal sera
In PHA-stimulated lymphocyte cultures
test sera or purified IgG were added before
the addition of PHA.
Purification ofImnmunoglobulin G.-Whole
serum was precipitated with 50% ammonium
sulphate and the sediment dialysed against
0-01 M phosphate buffer, pH 7-5. IgG was
obtained by column separation on DEAE
cellulose (Servacel DE 52, Seiva, Heidelberg,
Germany) previously equilibrated with this
buffer. Protein not absorbed under these
conditions was dialysed against phosphate-
buffered saline, pH 7-3, concentrated to the
original serum volume by ultrafiltration,
and passed through a millipore filter (0.22
,um). These fractions contained only IgG
as judged by immunoelectrophoresis; a
quantitative measurement was obtained by
radial immunodiffusion.
Patients.-All meningioma patients were
tested within 1 week before surgery and
retested between 7 and 15 days after total
excision of their tumour. No attempt was
made to eliminate donors with leucocytosis,
transfusion history, or complicating infec-
tions. All patients with CNS tumours had
received DXM for 1-8 days when first tested,
the mean dosage being 12-16 mg a day i.v.
Details of treatment are given in Table I.
Control donors were healthy volunteers
or patients with brain tumours of different
histological type including glioblastomas and
brain metastases.
RESULTS
Effect of surgery on lymphocyte cytotoxicity
(CTX)
Meningioma explants usually gre was
a 2-dimensional reticulum oflarge, spindle-
shaped cells. Sometimes typical psam-
moma bodies appeared even in later
passages (Fig. 1).
Seven meningioma patients could be
tested both before and shortly after
surgery. Three showed a specific destruc-
tion of meningioma cells (27-84% CTX)
when tested preoperatively, 2 were nega-
tive and another 2 met the criteria of
a " non-specific " response. It is note-
worthy that in these latter cases an
almost total destruction of tumour cells
was observed early in the incubation
period. This phenomenon did not cor-
relate with transfusion history, recent
infection or the composition of effector
cells. "Non-specific " CTX on menin-
gioma cells decreased only slightly after
surgery, whereas allogeneic fibroblasts
were much less affected postoperatively.
As can be seen from Table I and
Fig. 2, negative cases remained un-
changed, and 2/3 patients positive before
surgery became negative. Experiments
were also performed using glioblastoma
target cells (I.F.) to investigate the
specificity of the reaction further. In
no case did lymphocytes reacting specific-
ally on meningioma targets show a
significant destruction of glioblastoma
cells.
Influence of treatment with dexamethasone
on CTX
No correlation could be found between
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TABLE I.-Effect ofSurgery on Lymphocytotoxicity for Meningioma Cells and Allogeneic
Fibroblasts*
Target cell
Meningioma %Aedc
Lymphocyte
Exp. donor
Ia Ref. donor I
Meningioma I
lb Ref. donor II
Meningioma I
Ila Ref. donor III
Meningioma II
Ilb Ref. donor III
Meningioma II
IlIa Ref. donor I
Meningioma III
IlIb Ref. donor IV
Meningioma III
IVa Ref. donor V
Meningioma III
Meningioma IV
Meningioma V
IVb Ref. donor V
Meningioma IV
Meningioma V
Va Ref. donor VI
Meningioma VI
Vb Ref. donor II
Meningioma VI
Residual
Treatment ct/mint
1993 i493
192±55
2464± 199
314±37
1910±110
1183±102
1093 +174
1119± 186
DXM 8 days
DXM 15 days,
7 days post excis.
DXM 1 day
DXM 8 days,
6 days post excis.
1976± 72
DXM 4 days 1452±239
1963±i136
DXM 22 days, 1898±24
11 days post excis.
No DXM, 18 days
post excis.
DXM 3 days
DXM 2 days
No DXM, 12 days
post excis.
No DXM, 8 days
post excis.
DXM 8 days
No DXM, 15 days
post excis.
VIa Ref. donor VII
Meningioma VII DXM 2 days
VIb Ref. donor VIII
Meningioma VII No DXM, 8 days
post excis.
2269± 223
2169±91
2148± 192
354±161
644± 110
793± 85
323±92
4372± 127
4426±225
1293± 144
1245±127
2234± 148
129±31
2451±275
573 ± 77
% Reduc-
tiont
90¶
87¶
Fibrob
Residual
ct/min
3184± 121
181+65
2523 ±89
995±263
- 5531±338
38T 5919±137
3962±185
0 3994±306
4185±187
27T 4146±492
2297±823
N.S. 3130±383
2141±174
N.S. 1820±82
N.S. 1973±186
84¶ 1777±201
1592±112
0 1605±56
50¶ 1495±131
- 1903±130
0 1604±281
1516±67
N.S. 1566±89
- 4435±746
94¶ 2451 ±475
- 1238±93
77¶ 1244±83
lasts
% Reduc- Interpreta-
tion tion§
94¶ Non-specific
61¶ Non-specific
0 Specific
0 Negative
N.S. Specific
0 Negative
N.S.
N.S.
N.S.
0
N.S.
Negative
Negative
Specific
Specific
Negative
Specific
N.S. Negative
0 Negative
45¶
0
Non-specific
Specific
* Data of reference donors and meningioma patients only.
t Mean 3H-ct/min ± s.d. (n = 6) after 50 h of incubation. Ratio effector cells: target cells 200: 1.
I Relative to reference donor.
§ Specific - at least 20% reduction only on meningioma cells. Non-specific = at least 20% reduction
on meningioma cells and fibroblasts.
11 Duration of treatment with dexamethasone (DXM see text).
¶ Significant at P < 0 05 by Wilcoxon's test.
N.S. Not significant.
preoperative CTX and duration oftherapy
with DXM. Likewise, postoperative re-
sponses did not show any relation to
the total dosage of steroids given at
that time. When treatment ceased, no
increase of CTX could be observed in
previously positive (Nos. III, V) or
negative patients (Nos. IV, VI).
Blocking experiments
Autologous serum collected before
surgery inhibited CTX: an "arming"
effect was not observed (Table II). In
one patient (C.F.) showing a specific
response even after surgery, the post-
operative serum had decreased blocking
activity. In order to test the specificity
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FIG. 1.-Meningioma J.S., passage 2; phase contrast. x 95.
BEFORE
SURGERY
x
0
0
0
AFTER
SURGERY
FIG. 2. Cytotoxicity ofmeningioma patients
before and within 2 weeks after surgery.
Open circles, " non-specific " CTX.
of this inhibitory effect, lymphocytes
from patient K.L. were incubated on
allogeneic fibroblasts and meningioma
cells using both normal and autologous
serum. Since in normal serum destruc-
tion of all targets occurred and autologous
serum was able to suppress this effect,
the conclusion seems to be justified that
this blocking activity was "non-specific".
Relation to blood group sub8tances
Agglutination of contaminating red
blood cells in the effector cell preparations
by certain test sera was observed, as
expected from blood group differences.
A cytotoxic effect, however, did not occur
even in those combinations where test
sera contained isoantibodies directed
against blood group antigens of the target
cell donor (ABO system). No attempt
was made to test the expression of these
antigens on the target cells in question.
I
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TABLE II.-Inhibition of Lymphocytotoxicity by Sera from Meningioma Patients before
and after Surgery
% Reduction relative
to reference donor
after incubation with
A_<
Target cell
Meningioma (R.M.)
Meningioma (R.M.)
Meningioma (E.K.)
Meningioma (J.S.)
Meningioma (J.S.)
Meningioma (J.S.)
Meningioma (C.F.)
Meningioma (J.S.)
Meningioma (J.S.)
Meningioma (M.Z.)
Skin fibroblasts (A.N.)
Meningioma (K.L.)
Control
serum
38
0
6
27
3
84
50
0
94
45
77
Patient's
serum
27
0
iN.S. 0
16
N.S. 6 N.S.
50
40
12 N.S.
N.S. 0
9N.S.
44N.S.
10 N.S.
Blocking$
29
41
40
20
90
91
87
* See Table I.
t Date of drawing blood for both lymphocytes and patients' sera relative to surgery.
% Blocking % CTX in normal serum - % CTX in autologous serum x 100. Blocking.% CTX in normal serum
N.S. Not significant.
Lymphocyte culture
Table III summarizes the results of
PHA stimulation in 5 meningioma pa-
tients compared to normal donors. In
no case could a decrease of DNA synthesis
be seen after prolonged steroid adminis-
tration. On the contrary, in 2 patients,
an increase of thymidine incorporation
was observed postoperatively. No sig-
nificant difference could be demonstrated
in autologous sera before and after
surgery. One patient (E.K.) had a repro-
ducible inhibitory activity in his serum
when tested on allogeneic normal lympho-
cytes. Separation procedures revealed
that this effect was associated with a
fraction containing only IgG (Table IV).
There was no history of multiple preg-
nancies or transfusions in this donor.
DISCUSSION
Previous studies of other authors
(O'Toole et al., 1972b) and from our own
laboratory (Pees and Seidel, 1976) have
suggested that cell-mediated immunity
as measured in vitro by a microcytotoxi-
city assay might depend on the presence
of a critical tumour mass in the body.
In meningioma patients the highest re-
sponse rate was seen during the first
3 weeks. The observation of a rapidly
disappearing CTX in one patient tested
on several occasions postoperatively
prompted us to test the effect of surgery
on CTX in these tumours.
Our results demonstrate a marked
decrease or even disappearance of CTX
following surgery. In all patients the
tumour had been removed completely.
However, since there is now widespread
conviction that dexamethasone may dra-
matically reduce peri-tumoral oedema
(Fishman, 1975), a considerable number
of patients with CNS tumours will be
treated with this drug for a certain period
before and after surgery. Thus, most
of our patients were receiving treatment
already when they were admitted to
the department of neurosurgery. We
therefore decided to test all patients
during therapy, though we were aware
that the immunological situation would
be even more complex.
Exp.*
Ila
IIb
lIla
IlIb
IVa
lVb
Va
Vb
VIa
Immune
lymphocyte
donor
(meningioma)
E.K.
L.H.
C.F.
E.H.
K.L.
Treatmentt
Before
After
After
Before
After
Before
After
Before
After
Before
Before
After VIb
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TABLE III.-PHA Stimulation ofLympho-
cytes from Meningioma Patients. Effect
of Treatment and Autologous Sera vs
Normal Sera Relative to Untreated Con-
trol Donors
Lymphocyte
donor
H.P. Control
E.K. Meningioma
G.R. Control
R.W. Control
L.H. Meningioma
H.P. Control
C.F. Meningioma
C.P. Meningioma
R.L.
H.P.
E.H.
Control
Control
Meningioma
C.D. Control
K.L. Meningioma
* Mean CPM (n =
t Referring only
sera.
Source,
of
serum
hp 4t
E.K.
hp 4
E.K.
hp 4
L.H.
hp 4
L.H.
hp 4
L.H.
H.P.
C.F.
C.P.
H.P.
C.F.
C.P.
H.P.
C.F.
C.P. J
3H-ct/min*
AA
Before
surgeryt
31678
7694
25976
25374
25894
29668f
N.T.
33401
32581
26316
34721
34387
7659
9034
7937
N.T.
After
surgeryt
24590
13186
24238
22949
N.T.
38172
30555
31668
30122
10090
10477
10714
15899
17568
12725
13153
13903
12503
hp 5 46151 N.T E.H. 46030
hp5} N.T. 24603 E.H. ** 29152
hp 5 22842 26956
E.H. 21938 27169
hp 5 NT
36151
K.L. f 39475
hp 5 NT
19906
K.L. f 19225
= 5).
to patients' lymphocytes and
t hp = pooled sera from normal donors.
N.T. = not tested.
Evidence against DXM-induced sup-
pression of lymphocyte functions in the
studies reported here is two-fold. Firstly,
a comparison of the data given in Table I
demonstrates that all types of reaction
are detectable before surgery, irrespective
of the total dosage of DXM administered
at that time. Secondly, when hydro-
cortisone (OHC) is given in a single
injection of 400 mg to normal donors, it
causes a profound lymphopenia in the
peripheral blood which is reversible within
12-24 h. It has been shown that this
TABLE IV.-Effect of Patient IgG (E.K.)
on the Proliferative Response of Normal
Lymphocytes to PHA
Source of serum
Normal pooled serum
(hp 4)
Patients' serum
(E.K. before surgery)
hp 4 whole serum +
hp 4 IgGt
hp 4 whole serum +
hp 4 IgG
hp 4 whole serum +
hp 4 IgG
hp 4 whole serum A
E.K. IgGt
hp 4 whole serum +
E.K. IgG
hp 4 whole serum +
E.K. IgG
Final
concentration
in culture 3H-ct/min*
5/ 34479
5%
5%
5%
5%
10%
5%
15%
5%
5%
5%
10%
5%
15%}
17645
27849
23754
22459
220101
16312.
14322t
* Mean of 5 tests.
t Fraction containing only IgG after separation
on SERVACEL DEAE 52 (hp 4 IgG 280 mg/100 ml;
E.K. IgG 330 mg/100 ml).
I P < 0 05 by Wilcoxon's test in relation to
corresponding concentrations ofhp 4 IgG.
phenomenon is due to sequestration of
peripheral T cells into the bone marrow
(Cohen, 1972; Fauci and Dale, 1974;
1975). Therefore, measuring T-cell func-
tion in the peripheral blood, in common
with ability to respond to PHA (Lohr-
mann, Novikovs and Graw, 1974), should
provide a means of investigating this
redistribution effect. However, we were
not able to demonstrate any significant
difference in the response to PHA before
and after surgery, i.e. after prolonged
treatment with DXM.
Taken together, the following explana-
tions should be considered:
(a) DXM does indeed suppress CTX
by depletion of T cells. However, PHA
stimulation is not an appropriate means
to test this hypothesis. Hydrocortisone
might selectively deplete functional sub-
populations, i.e., Con A- and Pokeweed-
responsive cells, without significantly af-
fecting PHA-responsiveness (Fauci and
Dale, 1974).
(b) DXM does not inhibit lymphocyte
function when administered in the dosage
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used in our study. Unfortunately, exact
information in regard to equivalent doses
of OHC and DXM in this context is still
lacking.
(c) Our finding of a " normal " cyto-
toxic response during treatment with
DXM might indicate a major role for
a steroid-insensitive, possibly thymus-
independent lymphocyte. Indeed, the
effector cell in the cytotoxic system
described here is supposed to be a " null
cell ", i.e. a thymus-independent, IgG-
negative cell with receptors for C3 and
Fc (O'Toole et al., 1974; Brier, Chess and
Schlossman, 1975). Under certain condi-
tions such as neoplasia and prolonged
treatment with prednisone and cytosta-
tics, the percentage of "null cells" in
the peripheral blood is elevated (Yu et
al., 1974).
Our studies are in contrast with
other reports, where high degrees of CTX
were still detectable at more than 10 years
after successful surgery of malignant
brain tumours (Kumar et al., 1973).
Technical as well as immunological dif-
ferences between benign and malignant
CNS tumours might account for some of
these divergent results.
Brooks et at. (1972) described an
inhibition of the blastogenic response to
tumour-specific membrane antigens and
PHA by autologous sera in patients with
intracranial tumours, including menin-
giomas. Only one patient in our series
had such a suppressor activity directed
against allogeneic lymphocytes and asso-
ciated with the IgG fraction of his serum.
Thomas, Lannigan and Behan (1975)
found depression of PHA-induced protein
synthesis in gliomas, but not in benign
brain tumours.
The blocking activity which could be
demonstrated in some sera in the cytotoxic
assay turned out to be not specific for
meningiomas. Interestingly, with one ex-
ception, the same sera did not inhibit
response to PHA. Blocking phenomena
are due to different substances, like
specific antigens, complexes of antigen
and antibody, and totally unrelated im-
mune complexes acting via the Fc-
receptor (Currie and Basham, 1972; Sak-
sela, Penttinen and Pyrhonen, 1974).
We have shown recently that immuno-
suppression in cancer sera is related to
the presence of micromolecular fibrinogen
degradation products (Girmann et al.,
1976). However, since these substances
not only inhibit CTX of meningioma
patients (Pees and Girmann, unpublished
observations) but also strongly suppress
PHA-stimulation, they are less likely to
be involved here.
Another intriguing question is the
phenomenon of CTX directed against
targets of different histogenic origin,
often referred to as " non-specific " CTX.
Two patients in our study showed this
type of response. It has been claimed
(Unsgaard and O'Toole, 1975) that mye-
loid precursor cells, often found in the
peripheral blood of patients with meta-
stases, are responsible for the killing
of unrelated target cells in vitro. Our
patients did not have clinical evidence
of metastasis, weight loss or haemato-
logical abnormalities. We should em-
phasize that the term " non-specific "
is by no means equivalent to "non-
immunological" and should not preclude
careful analysis of this phenomenon.
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